First Experience with Osimertinib in Patients with Newly Developed T790M Mutation Previously Treated with EGFR - TKIs in Croatia

被引：0
|
作者：
Jakopovic, M. [1 ]
Bitar, L. [1 ]
Seiwerth, F. [1 ]
Plestina, S. [1 ]
Kukulj, S.
Seiwerth, S. [2 ,3 ]
Misic, M. [3 ]
Redzepi, G. [1 ]
Samarzija, M. [2 ]
机构：
[1] Univ Hosp Ctr Zagreb, Dept Resp Dis Jordanovac, Zagreb, Croatia
[2] Univ Hosp Ctr Zagreb, Zagreb, Croatia
[3] Univ Hosp Ctr Zagreb, Clin Dept Pathol, Zagreb, Croatia
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
D O I：
10.1016/j.jtho.2017.09.1500
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.01-059
引用
收藏
页码：S2224 / S2224
页数：1
相关论文
共 50 条
  • [21] Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation
    Watanabe, Kana
    Saito, Ryota
    Miyauchi, Eisaku
    Nagashima, Hiromi
    Nakamura, Atsushi
    Sugawara, Shunichi
    Tanaka, Nobuyuki
    Terasaki, Hiroshi
    Fukuhara, Tatsuro
    Maemondo, Makoto
    CANCERS, 2023, 15 (17)
  • [22] Prevalence of EGFR T790M mutation in NSCLC patients after afatinib failure, and subsequent response to osimertinib
    Hochmair, Maximilian
    Schwab, Sophia
    Burghuber, Otto
    Koger, Renate
    Setinek, Ulrike
    Cseh, Agnieszka
    Fritz, Richard
    Buder, Anna
    Filipits, Martin
    WIENER KLINISCHE WOCHENSCHRIFT, 2017, 129 (19-20) : 776 - 776
  • [23] Prevalence of EGFR T790M Mutation in NSCLC Patients after Afatinib Failure, and Subsequent Response to Osimertinib
    Hochmair, M.
    Schwab, S.
    Burghuber, O.
    Koger, R.
    Setinek, U.
    Cseh, A.
    Fritz, R.
    Buder, A.
    Filipits, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2136 - S2136
  • [24] Osimertinib Depletes EGFR T790M in the Spinal Fluid of Patients with Carcinomatous Meningitis of Lung Adenocarcinoma Harboring De Novo EGFR T790M
    Senoo, Satoru
    Ohashi, Kadoaki
    Nishii, Kazuya
    Hara, Naofumi
    Kano, Hirohisa
    Ninomiya, Kiichiro
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) : E140 - E142
  • [25] T790M Mutation and Clinical Outcomes with Genuine Osimertinib
    Parikh, Purvish M.
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2019, 40 (01) : 7 - 8
  • [26] EGFR T790M mutation testing within the osimertinib AURA Phase I study
    Dearden, Simon
    Brown, Helen
    Jenkins, Suzanne
    Thress, Kenneth S.
    Cantarini, Mireille
    Cole, Rebecca
    Ranson, Malcolm
    Janne, Pasi A.
    LUNG CANCER, 2017, 109 : 9 - 13
  • [27] Detection of T790M mutation in EGFR gene, an EGFR-TKI resistant mutation, in tumor samples unexposed to EGFR TKIs
    Koba, Hayato
    Kimura, Hideharu
    Nishikawa, Shingo
    Yoneda, Taro
    Sone, Takashi
    Kasahara, Kazuo
    CANCER RESEARCH, 2016, 76
  • [28] Progressive Disease with T790M Mutation vs Non-T790M Mutation in EGFR Positive Patients Treated with Tyrosine Kinase Inhibitors
    Reis, D.
    China, N.
    Dias, M.
    Coutinho, D.
    Silva, E.
    Campainha, S.
    Costa, T.
    Conde, S.
    Cirnes, L.
    Barroso, A.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S942 - S943
  • [29] EGFR T790M Mutation Detection and Osimertinib Treatment Response Evaluation by Liquid Biopsy in Advanced NSCLC Patients
    Li, C.
    Liu, H.
    Zhang, B.
    Zhang, Z.
    Su, Y.
    Wang, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2141 - S2142
  • [30] Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR
    Sakai, Hitomi
    Hayashi, Hidetoshi
    Iwasa, Tsutomu
    Hasegawa, Yoshikazu
    Takeda, Masayuki
    Nakagawa, Kazuhiko
    ESMO OPEN, 2017, 2
12345